Charles Holladay, MD
Hematology & Oncology · North Charleston, SCNPI 1215929542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 562 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.8% — the pattern of someone who eats at a lot of different presentations.
Across 562 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1K
- Novartis$964
- Johnson & Johnson$848
- E.r. Squibb & Sons, L.L.C.$681
- Gilead$611
- AstraZeneca$582
- plus $7K from 54 others
Across 88 payments — averaging $2330.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$105K
- Pfizer$41K
- Amgen$22K
- Incyte Corporation$15K
- Janssen Research & Development, LLC$9K
- Pharmacyclics LLC, An Abbvie Company$7K
- plus $7K from 3 others
What the payments were for
- Food & beverage$11,06997%
- Education$3403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,409 in reported general payments places this provider in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 61 | $1,095,360 |
| XtandiEnzalutamide | 70 | $963,634 |
| CalquenceAcalabrutinib Maleate | 37 | $567,811 |
| PomalystPomalidomide | 18 | $417,720 |
| CabometyxCabozantinib S-Malate | 12 | $358,291 |
| KisqaliRibociclib Succinate | 19 | $312,084 |
| RevlimidLenalidomide | 16 | $273,687 |
| TabrectaCapmatinib Hydrochloride | 12 | $255,424 |
| TagrissoOsimertinib Mesylate | 13 | $212,475 |
| VerzenioAbemaciclib | 12 | $209,937 |
| JakafiRuxolitinib Phosphate | 12 | $201,015 |
| TasignaNilotinib Hcl | 11 | $134,793 |
| GilotrifAfatinib Dimaleate | 12 | $129,137 |
| PromactaEltrombopag Olamine | 14 | $96,071 |
| Imatinib Mesylate | 28 | $57,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $72 | $1,095,36061 claims |
| Astellas Pharma US IncXtandi | $229 | $963,63470 claims |
| NovartisKisqali, Tabrecta, Tasigna, Promacta | $964 | $798,37256 claims |
| AstraZenecaCalquence, Tagrisso | $582 | $780,28750 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $681 | $417,72018 claims |
| Exelixis Inc.Cabometyx | $131 | $358,29112 claims |
| Bristol Myers SquibbRevlimid | $1,006 | $273,68716 claims |
| Lilly USA, LLCVerzenio | $235 | $209,93712 claims |
| Incyte CorporationJakafi | $183 | $201,01512 claims |
| Boehringer IngelheimGilotrif | $27 | $129,13712 claims |
| PfizerEliquis | $546 | $43,65551 claims |
| Johnson & JohnsonXarelto | $848 | $23,02019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in North Charleston
- Julia SaylorsNorth Charleston$20K
- Douglas MichaelsenNorth Charleston$16K
- Ashley JeterNorth Charleston$15K
- Matthew BeldnerNorth Charleston$9K
- Margaret BradyNorth Charleston$9K
- Jenny RileyNorth Charleston$9K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.